Drug Trial Radar · NCT05688280
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS
Last checked: Nov 20, 2026Latest source record: Jan 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
42
Actual
Start
Nov 29, 2022
Primary completion
Feb 2025
Study completion Feb 2025
Sponsor
- Lead sponsor
- Immunophotonics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to determine the safety and efficacy of IP-001 for intratumoral injection administration following thermal ablation of a solid tumor.
Conditions
- Metastatic Solid Tumor
- Colon Cancer
- Nonsmall Cell Lung Cancer
- Soft Tissue Sarcoma
Interventions
1.0% IP-001 for InjectionDrug
4 mL 1.0% IP-001 for Injection following RFA every 6 weeks for up to 4 treatments.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and TolerabilityTime frame: Up to 12 weeks
Locations
16 sites in 5 countries. Site status is shown where the registry gives one.
Miami Cardiac & Vascular Institute
Coral Gables, Florida
University of Louisville Physicians, PSC
Louisville, Kentucky
Stephenson Cancer Center
Oklahoma City, Oklahoma
Institut Bergonie
Bordeaux, France
Hospitalier Pitie-Salpetriere
Paris, France
Hôpital Foch
Suresnes, France
Institut Gustave Roussy
Villejuif, France
Johann Wolfgang Goethe-Univresitat Frankfurt/Main
Frankfurt, Germany
SLK-Kliniken Heilbronn GmbH
Heilbronn, Germany
Munchen Klinik Bogenhausen
Munich, Germany
IOSI Ospedale San Giovanni Bellinzona
Bellinzona, Switzerland
Inselspital Universitatsspital, Bern
Bern, Switzerland
Kantonsspital Graubunden
Chur, Switzerland
Kantonsspital St. Gallen
Sankt Gallen, Switzerland
University College London Hospitals
London, United Kingdom
Churchill Hospital
Oxford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.